Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biopharma crawled date : 2021 - 11 - 01 save search
Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 1.63%
H: 3.5%
C: 2.92%
hepatitis biopharma phase 3 lonafarnib enroll
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and Partnerships
Published: 2021-11-01 (Crawled : 13:00) - prnewswire.com
LTRN | News | $5.93 2.77% 38K
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: -2.6%
partnership biopharma potential collaboration drug platform
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
RCAT | $1.52 26.67% 1.3M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.